My Portfolio

AstraZeneca PLC AZN-GB:London Stock Exchange

RT Quote | Exchange | GBp

Last | 06/03/26 BST

13,210.00UNCH (UNCH)

52 week range

10,103.00 - 15,732.00

Open0.00
Day High0.00
Day Low0.00
Prev Close13,210.00
52 Week High15,732.00
52 Week High Date02/18/26
52 Week Low10,103.00
52 Week Low Date07/01/25

Latest On AstraZeneca PLC

AstraZeneca CEO: AI is affecting every part of our company8 Hours AgoCNBC.com
How investors are trading the UK as political turmoil rattles British marketsMay 21, 2026CNBC.com
Weight-loss wars go global as Novo Nordisk bets big on its Wegovy pillMay 18, 2026CNBC.com
Bristol Myers Squibb turns to China to develop new drugsMay 15, 2026CNBC.com
Stocks making the biggest moves premarket: Apple, Estee Lauder, Roku, RedditMay 1, 2026CNBC.com
AstraZeneca stock falls after FDA panel votes against new cancer drugMay 1, 2026CNBC.com
UK's biggest drugmakers see profit bump, as pharma grapples with U.S. policiesApril 29, 2026CNBC.com
Dow slides more than 250 points, posting a fifth day of losses, as oil prices riseApril 28, 2026CNBC.com
Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'April 28, 2026CNBC.com
Trump policies, China's biotech boom are ending Europe's pharma powerhouse eraApril 11, 2026CNBC.com

Key Stats

Market Cap204.887B
Shares Out1.55B
10 Day Average Volume1.86M
Dividend236.20
Dividend Yield1.79%
Beta0.91

Latest On AstraZeneca PLC

AstraZeneca CEO: AI is affecting every part of our company8 Hours AgoCNBC.com
How investors are trading the UK as political turmoil rattles British marketsMay 21, 2026CNBC.com
Weight-loss wars go global as Novo Nordisk bets big on its Wegovy pillMay 18, 2026CNBC.com
Bristol Myers Squibb turns to China to develop new drugsMay 15, 2026CNBC.com
Stocks making the biggest moves premarket: Apple, Estee Lauder, Roku, RedditMay 1, 2026CNBC.com
AstraZeneca stock falls after FDA panel votes against new cancer drugMay 1, 2026CNBC.com
UK's biggest drugmakers see profit bump, as pharma grapples with U.S. policiesApril 29, 2026CNBC.com
Dow slides more than 250 points, posting a fifth day of losses, as oil prices riseApril 28, 2026CNBC.com
Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'April 28, 2026CNBC.com
Trump policies, China's biotech boom are ending Europe's pharma powerhouse eraApril 11, 2026CNBC.com

KEY STATS

Open0.00
Day High0.00
Day Low0.00
Prev Close13,210.00
52 Week High15,732.00
52 Week High Date02/18/26
52 Week Low10,103.00
52 Week Low Date07/01/25
Market Cap204.887B
Shares Out1.55B
10 Day Average Volume1.86M
Dividend236.20
Dividend Yield1.79%
Beta0.91

RATIOS/PROFITABILITY

EPS (TTM)507.54
P/E (TTM)26.03
Fwd P/E (NTM)-
EBITDA (TTM)15.143B
ROE (TTM)23.51%
Revenue (TTM)44.933B
Gross Margin (TTM)81.42%
Net Margin (TTM)17.20%
Debt To Equity (MRQ)71.66%

EVENTS

Earnings Date-
Ex Div Date02/19/2026
Div Amount1.595
Split Date-
Split Factor-

Content From Our Affiliates

Citi Remains a Buy on AstraZeneca (AZN)10 Hours AgoTipRanks
Guggenheim Sticks to Its Buy Rating for AstraZeneca (AZN)11 Hours AgoTipRanks
AstraZeneca’s ASCEND Obesity Trial Completion Puts New Weight Loss Combo in Focus12 Hours AgoTipRanks
FDA issues draft guidance to help accelerated cell, gene therapies for patientsJune 2, 2026TipRanks
AstraZeneca announces additional results from Phase III Serena-6 trialJune 2, 2026TipRanks

Profile

AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu....

Michel Demare

Non-Executive Independent Chairman of the Board

Pascal Soriot

Chief Executive Officer, Executive Director

Aradhana Sarin M.D.

Chief Financial Officer, Executive Director

Ruud Dobber Ph.D.

Executive Vice President - Bio Pharmaceuticals Business Unit

Susan Galbraith

Executive Vice President - Oncology Haematology Research and Development

Address

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge

CB2 0AA

United Kingdom

https://www.astrazeneca.com/